La Universidad permanecerá cerrada del 11 al 15 de agosto.
 

Cellular stress responses as modulators of drug cytotoxicity in pharmacotherapy of glioblastoma

Loading...
Thumbnail Image

Full text at PDC

Publication date

2024

Advisors (or tutors)

Editors

Journal Title

Journal ISSN

Volume Title

Publisher

Elsevier
Citations
Google Scholar

Citation

Kusaczuk, M., Ambel, E. T., Naumowicz, M., & Velasco, G. (2024). Cellular stress responses as modulators of drug cytotoxicity in pharmacotherapy of glioblastoma [Review of Cellular stress responses as modulators of drug cytotoxicity in pharmacotherapy of glioblastoma]. Biochimica et Biophysica Acta - Reviews on Cancer, 1879(1). Elsevier B.V. https://doi.org/10.1016/J.BBCAN.2023.189054

Abstract

Despite the extensive efforts to find effective therapeutic strategies, glioblastoma (GBM) remains a therapeutic challenge with dismal prognosis of survival. Over the last decade the role of stress responses in GBM therapy has gained a great deal of attention, since depending on the duration and intensity of these cellular programs they can be cytoprotective or promote cancer cell death. As such, initiation of the UPR, autophagy or oxidative stress may either impede or facilitate drug-mediated cell killing. In this review, we summarize the mechanisms that regulate ER stress, autophagy, and oxidative stress during GBM development and progression to later discuss the involvement of these stress pathways in the response to different treatments. We also discuss how a precise understanding of the molecular mechanisms regulating stress responses evoked by different pharmacological agents could decisively contribute to the design of novel and more effective combinational treatments against brain malignancies.

Research Projects

Organizational Units

Journal Issue

Description

This work was supported by Polish National Agency for Academic Exchange (NAWA) within the frames of the Bekker Programme PPN/BEK/2020/1/00105 and the Medical University of Bialystok (SUB/2/DN/21/002/2205 and B.SUB.23.371) and Instituto de Salud Carlos III (ISCIII) and cofounded by the European Regional Development Fund (ERDF). “A way to make Europe”, grant numbers PI18/00442 integrated into the State Plan for R & D + I 2017–2020 and PI21/00343 integrated into the State Plan for R & D + I 2021–2023 and the Grant ASAP-CM, funded by the Programa de Actividades de I + D entre grupos de investigación de la Comunidad de Madrid en Biomedicina 2022.

Keywords

Collections